Rhythm Pharmaceuticals Inc. [NASDAQ: RYTM] closed the trading session at $42.42.
The stocks have a year to date performance of -7.72 percent and weekly performance of 6.40 percent. The stock has been moved at -6.00 percent over the last six months. The stock has performed 12.07 percent around the most recent 30 days and changed 3.74 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 558.37K shares, RYTM reached to a volume of 332881 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Rhythm Pharmaceuticals Inc. [RYTM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RYTM shares is $57.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RYTM stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Rhythm Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 08, 2024. While these analysts kept the previous recommendation, Morgan Stanley raised their target price from $29 to $55. The new note on the price target was released on December 19, 2023, representing the official price target for Rhythm Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $22 to $27, while BofA Securities kept a Buy rating on RYTM stock.
The Average True Range (ATR) for Rhythm Pharmaceuticals Inc. is set at 1.99, with the Price to Sales ratio for RYTM stock in the period of the last 12 months amounting to 28.13. The Price to Book ratio for the last quarter was 42.00, with the Price to Cash per share for the same quarter was set at 3.30.
RYTM stock trade performance evaluation
Rhythm Pharmaceuticals Inc. [RYTM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.40. With this latest performance, RYTM shares gained by 12.07% in over the last four-week period, additionally sinking by -6.00% over the last 6 months – not to mention a rise of 162.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RYTM stock in for the last two-week period is set at 56.16, with the RSI for the last a single of trading hit 48.08, and the three-weeks RSI is set at 50.65 for Rhythm Pharmaceuticals Inc. [RYTM]. The present Moving Average for the last 50 days of trading for this stock 39.89, while it was recorded at 41.40 for the last single week of trading, and 37.67 for the last 200 days.
Rhythm Pharmaceuticals Inc. [RYTM]: An insightful look at the core fundamentals
Rhythm Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.20 and a Current Ratio set at 4.35.
Earnings per share (EPS) analysis for Rhythm Pharmaceuticals Inc. [RYTM] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RYTM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rhythm Pharmaceuticals Inc. go to -9.00%.
Rhythm Pharmaceuticals Inc. [RYTM]: Institutional Ownership
The top three institutional holders of RYTM stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in RYTM stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in RYTM stock with ownership which is approximately 5.1238%.
